Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

American Cancer Society Study Links 12% of Colorectal Cancer Deaths to Cigarettes

February 1, 2001
Publication
Article
OncologyONCOLOGY Vol 15 No 2
Volume 15
Issue 2

In the largest prospective study of cigarette smoking and colorectal cancer mortality, researchers from the American Cancer Society report finding strong evidence that cancers of the colon and rectum are, in part, smoking related.

In the largest prospective study of cigarette smokingand colorectal cancer mortality, researchers from theAmerican Cancer Society report finding strong evidence that cancers of the colonand rectum are, in part, smoking related.

An analysis of the American Cancer Society’s Cancer PreventionStudy II appeared in a recent issue of the Journal of the National CancerInstitute (92:1888-1896, 2000). It concluded that not only is long-termcigarette smoking associated with an elevated risk of dying of colorectalcancer, but that about 12% of 1997 deaths from this cancer may be attributableto cigarette smoking.

Lowest Rates Among Nonsmokers

Ann Chao, PhD, Michael J. Thun, MD, and colleagues at theAmerican Cancer Society report that colorectal death rates were highest amongcurrent smokers and lowest among those who never smoked. "Clear benefitswere also observed among those people who had quit smoking; the longer ago, thehigher the benefit," said Dr. Chao.

In the study, current male smokers had a 32% higher death ratethan nonsmokers, and current female smokers had a death rate of 41%. The higherdeath rates increased with duration of the habit and with the number ofcigarettes smoked daily.

The rates were higher for current smokers who began smokingcigarettes at younger ages, than among those who smoked longer and morecigarettes per day.

Study Data

The Cancer Prevention Study II began enrolling approximately1 million Americans in 1982. Dr. Chao and her coauthors analyzed data on312,332 men and 469,019 women, among whom 4,432 died from either colon or rectalcancer. Data from these participants were controlled for a number of potentiallyconfounding variables including alcohol use, physical activity, family historyof colorectal cancer, vitamin use, and dietary factors.

"The size of the study allowed us to examine, in detail,gradients in smoking behavior separately in former and current smokers,"said Dr. Chao. "It also permitted us to estimate the percentage ofsmoking-related colorectal cancer deaths in the general population, which wouldhave been about 12% in 1997, or more than 6,800 people for that year," shesaid.

"The smoking epidemic in women began decades later than inmen," said Michael J. Thun, MD, vice president of epidemiology andsurveillance research for the American Cancer Society. "This may explain,in part, why the trends in colorectal cancer incidence and death rates differedbetween genders during the 1950s, 1960s, and 1970s, with male rates being higherthan female rates. As the smoking rates increased for women, the colorectalrates became very similar for both genders," said Dr. Thun. 

Articles in this issue

Book Review: Comprehensive Cancer Care: Integrating Alternative, Complementary, and Conventional Therapies
Study Details Use of Amifostine in Radiation Setting
Declines in Lung Cancer Rates-California, 1988-1997
Medicare Approves PET for Additional Cancers
Study Contributes to Evolution of Sentinel Lymph Node Biopsy for Melanoma
The Breast: Comprehensive Management of Benign and Malignant Diseases, Second Edition
Topotecan Active as First-Line Combination Therapy for Advanced Non-Small-Cell Lung Cancer
Promising Results With Motexafin for Brain Metastases and Glioblastoma Multiforme
Chemoradiotherapy Followed by Docetaxel May Increase Life Expectancy in Non-Small-Cell Lung Cancer Patients
Medicare Bill Expands Cancer Screening
Researchers Able to Predict Which Breast Cancer Patients Are at Highest Risk of Bone Metastases
Letrozole Approved as First-Line Treatment for Advanced Breast Cancer in Postmenopausal Women
American Cancer Society Study Links 12% of Colorectal Cancer Deaths to Cigarettes
Painful Osteoblastic Metastases: The Role of Nuclear Medicine
Corticosteroids in Advanced Cancer
Recent Videos
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content
Advertisement

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Ariana Pelosci
November 18th 2025
Article

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer

Russ Conroy
November 14th 2025
Article

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Ariana Pelosci
November 12th 2025
Article

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.


Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

ELI-002 7P Elicits Robust T-Cell Responses in KRAS+ Pancreatic Cancer

Russ Conroy
November 11th 2025
Article

Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

Related Content
Advertisement

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Ariana Pelosci
November 18th 2025
Article

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer

Russ Conroy
November 14th 2025
Article

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Ariana Pelosci
November 12th 2025
Article

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.


Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

ELI-002 7P Elicits Robust T-Cell Responses in KRAS+ Pancreatic Cancer

Russ Conroy
November 11th 2025
Article

Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.